Oruka Reports Q2 2026 Results, $1.1B Cash, and Multiple Near-Term Catalysts
ORKA has more than doubled off its 52-week low of $12.84 on light trading volume (0.2× avg).
Summary
Oruka Therapeutics reported Q2 2026 results with $1.1 billion in cash, funding operations through a BLA filing for ORKA-001, and outlined multiple near-term clinical catalysts including EVERLAST-A Week 28 data by end of Q3 2026 and EVERLAST-B Week 16 data in Q4 2026.
Key Events · Earnings and Guidance · ORKA
-
Q2 2026 Financial Results
Net loss of $41.2 million on R&D spend of $43.3 million; cash, equivalents, and marketable securities total $1.1 billion as of June 30, 2026.
-
Cash Runway Through BLA Filing
Management expects the $1.1 billion cash position to fund operations through an anticipated BLA filing for ORKA-001, removing near-term financing overhang.
-
Multiple Near-Term Catalysts
EVERLAST-A Week 28 data expected end of Q3 2026; 52-week data in December 2026; EVERLAST-B Week 16 data in Q4 2026; ORCA-SURGE Week 16 data accelerated to Q1 2027.
-
Pipeline Expansion
Initiated ORCA-SPLASH Phase 2 trial in hidradenitis suppurativa; announced ORKA-004, a novel anti-TL1A antibody, entering clinic in Q4 2026 with Phase 2 combo studies planned for 2027.
Analysis · ORKA · Life Sciences
A pipeline-rich quarterly update from Oruka Therapeutics extends its cash runway through a BLA filing for lead candidate ORKA-001 and sets the stage for a series of high-impact clinical readouts over the next six months. The $1.1 billion cash position, bolstered by the recent $700 million offering, removes near-term financing risk and funds operations through a potential approval. Multiple catalysts are now on the calendar: EVERLAST-A Week 28 data by end of Q3 2026, 52-week data in December, EVERLAST-B Week 16 data in Q4 2026, and accelerated ORCA-SURGE data in Q1 2027. The initiation of ORCA-SPLASH in hidradenitis suppurativa and the unveiling of ORKA-004, a new TL1A-targeting asset entering the clinic in Q4 2026, broaden the pipeline beyond psoriasis. With the stock trading near its 52-week high, these updates reinforce the bull case but also raise the bar for execution — any miss on the upcoming readouts could reverse the recent gains.
At the time of this filing, ORKA was trading at $98.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $12.84 to $100.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.